How much weight can I lose with bariatric surgery?

Sleeve gastrectomy patients typically lose 25–30% of total body weight at one year, and gastric bypass patients lose 30–35%. Duodenal switch and SADI-S sit higher at 35–40%, while adjustable gastric band and endoscopic sleeve gastroplasty are in the 15–20% band. Real-world losses depend on how consistently you keep the post-op protein, follow-up, and activity plan; long-term maintenance at five years usually settles 5–10 percentage points below the one-year peak.

Sleeve vs bypass — which is better long-term?

The SM-BOSS (Peterli 2018) and SLEEVEPASS (Salminen 2018, 2022 10-yr extension) trials both compared sleeve and bypass head-to-head and reported similar total-weight-loss durability at 5 and 10 years. Bypass produced somewhat higher rates of type 2 diabetes remission and stronger GERD improvement; sleeve had fewer nutrient deficiencies and a simpler anatomy. Choose bypass if diabetes or reflux is the primary driver; choose sleeve if simplicity and lower long-term micronutrient burden matter more.

How safe is bariatric surgery in 2026?

The 30-day mortality benchmark at accredited U.S. centers is approximately 0.1% — comparable to gallbladder or hip-replacement surgery. Serious complications (leak, bleed, VTE) run 3–5% overall, driven mostly by revision cases and higher-BMI patients. Modern laparoscopic and robotic technique, accredited MBSAQIP centers, and enhanced-recovery protocols are the reasons the risk profile has fallen dramatically since the early 2000s.

Does insurance cover bariatric surgery?

Most U.S. commercial insurers and Medicare cover bariatric surgery when the patient meets BMI and comorbidity criteria and completes the plan-specific prior authorization — typically a supervised weight-loss attempt of 3–6 months, a psychological evaluation, nutrition classes, and treatment at an in-network MBSAQIP center. Coverage denials most often stem from missed documentation rather than clinical ineligibility. Self-pay bundles in the U.S. currently range from about $15,000 to $30,000.

Can I have bariatric surgery if I'm on a GLP-1?

Yes, and the combination is increasingly common. GLP-1s are used before surgery to reduce liver size and improve operative conditions, and after surgery for patients who regain weight or hit an inadequate-response plateau. Anesthesia teams typically pause GLP-1 dosing for 1–2 weeks pre-op to reduce aspiration risk from delayed gastric emptying. See the [bariatric surgery vs GLP-1 medications](/weight-loss/bariatric-surgery-vs-glp-1-medications/) comparison for the full decision picture.

How long is the recovery after bariatric surgery?

Most laparoscopic sleeve and bypass patients go home in 1–2 days, return to light activity in 1–2 weeks, and resume full work and normal activity by 4–6 weeks. Full return to exercise usually happens at 6 weeks after clearance. The eating protocol progresses through clear-liquid, full-liquid, pureed, and soft-food stages over roughly 6 weeks before returning to solid textures with strict portion limits.

What happens if I regain weight after surgery?

Some regain is normal — the STAMPEDE 5-year follow-up showed roughly 5–10 percentage points of regain from the 1-year weight-loss peak, and about 20–30% of patients experience larger regain. Structured follow-up, revisiting the post-op protein and activity plan, adding a GLP-1 medication, or in some cases [revisional surgery](/weight-loss/bariatric-surgery-revision/) are the main tools. Early re-engagement with the bariatric team is the strongest predictor of successful recovery.

Who does NOT qualify for bariatric surgery?

The main disqualifiers are active untreated substance use, untreated severe eating disorders, unstable mental illness that would compromise post-op adherence, active cancer treatment, severe uncorrectable cardiopulmonary risk, and pregnancy or planned pregnancy within 12–18 months. BMI is not the ceiling — many programs will operate above BMI 60 with staged approaches. Adolescents under 13, or Tanner stage under 3, are typically referred for further evaluation before surgery is considered.

2025-03-01 · surgical, bariatric, sleeve-gastrectomy, gastric-bypass, revision, weight-loss, obesity, T2D-remission

Updated 2026-07-24

Written by Nora Kim

Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.

12 min read

Medically reviewed on Jul 24, 2026

Editorial mosaic of a draped operating-room table, laparoscopic instrument tray, recovery-room vitals monitor, and a small bariatric portion meal.

How much weight can I lose with bariatric surgery?: Sleeve gastrectomy patients typically lose 25–30% of total body weight at one year, and gastric bypass patients lose 30–35%. Duodenal switch and SADI-S sit higher at 35–40%, while adjustable gastric band and endoscopic sleeve gastroplasty are in the 15–20% band. Real-world losses depend on how consistently you keep the post-op protein, follow-up, and activity plan; long-term maintenance at five years usually settles 5–10 percentage points below the one-year peak.
Sleeve vs bypass — which is better long-term?: The SM-BOSS (Peterli 2018) and SLEEVEPASS (Salminen 2018, 2022 10-yr extension) trials both compared sleeve and bypass head-to-head and reported similar total-weight-loss durability at 5 and 10 years. Bypass produced somewhat higher rates of type 2 diabetes remission and stronger GERD improvement; sleeve had fewer nutrient deficiencies and a simpler anatomy. Choose bypass if diabetes or reflux is the primary driver; choose sleeve if simplicity and lower long-term micronutrient burden matter more.
How safe is bariatric surgery in 2026?: The 30-day mortality benchmark at accredited U.S. centers is approximately 0.1% — comparable to gallbladder or hip-replacement surgery. Serious complications (leak, bleed, VTE) run 3–5% overall, driven mostly by revision cases and higher-BMI patients. Modern laparoscopic and robotic technique, accredited MBSAQIP centers, and enhanced-recovery protocols are the reasons the risk profile has fallen dramatically since the early 2000s.
Does insurance cover bariatric surgery?: Most U.S. commercial insurers and Medicare cover bariatric surgery when the patient meets BMI and comorbidity criteria and completes the plan-specific prior authorization — typically a supervised weight-loss attempt of 3–6 months, a psychological evaluation, nutrition classes, and treatment at an in-network MBSAQIP center. Coverage denials most often stem from missed documentation rather than clinical ineligibility. Self-pay bundles in the U.S. currently range from about $15,000 to $30,000.
Can I have bariatric surgery if I'm on a GLP-1?: Yes, and the combination is increasingly common. GLP-1s are used before surgery to reduce liver size and improve operative conditions, and after surgery for patients who regain weight or hit an inadequate-response plateau. Anesthesia teams typically pause GLP-1 dosing for 1–2 weeks pre-op to reduce aspiration risk from delayed gastric emptying. See the [bariatric surgery vs GLP-1 medications](/weight-loss/bariatric-surgery-vs-glp-1-medications/) comparison for the full decision picture.
How long is the recovery after bariatric surgery?: Most laparoscopic sleeve and bypass patients go home in 1–2 days, return to light activity in 1–2 weeks, and resume full work and normal activity by 4–6 weeks. Full return to exercise usually happens at 6 weeks after clearance. The eating protocol progresses through clear-liquid, full-liquid, pureed, and soft-food stages over roughly 6 weeks before returning to solid textures with strict portion limits.
What happens if I regain weight after surgery?: Some regain is normal — the STAMPEDE 5-year follow-up showed roughly 5–10 percentage points of regain from the 1-year weight-loss peak, and about 20–30% of patients experience larger regain. Structured follow-up, revisiting the post-op protein and activity plan, adding a GLP-1 medication, or in some cases [revisional surgery](/weight-loss/bariatric-surgery-revision/) are the main tools. Early re-engagement with the bariatric team is the strongest predictor of successful recovery.
Who does NOT qualify for bariatric surgery?: The main disqualifiers are active untreated substance use, untreated severe eating disorders, unstable mental illness that would compromise post-op adherence, active cancer treatment, severe uncorrectable cardiopulmonary risk, and pregnancy or planned pregnancy within 12–18 months. BMI is not the ceiling — many programs will operate above BMI 60 with staged approaches. Adolescents under 13, or Tanner stage under 3, are typically referred for further evaluation before surgery is considered.

Bariatric Surgery Overview

Bariatric surgery is the most effective treatment currently available for severe obesity — larger and more durable than lifestyle programs, medical weight-loss programs, or (in most patients) even the newer GLP-1 medications. Total weight loss of 25–35% at one year is the routine outcome for the two most common procedures, and the majority of that loss is still present at five and ten years when patients stay engaged with follow-up. This guide walks through what the four procedures currently on offer actually do, who qualifies under the 2022 ASMBS/NIH criteria, what the trial data show for weight loss and type 2 diabetes remission, what can go wrong, what it costs, and how it stacks up against the GLP-1s.

Quick stats

Typical excess-weight loss at 1 year: 55–70% after sleeve gastrectomy; 65–80% after Roux-en-Y gastric bypass; roughly 40–50% after adjustable gastric band.
Typical total-weight loss at 1 year: 25–30% for sleeve; 30–35% for gastric bypass; 35–40% for duodenal switch / SADI-S.
Type 2 diabetes remission at 1 year: 40–60% after sleeve; 50–70% after gastric bypass; 70–80% after duodenal switch (Schauer 2017 STAMPEDE 5-yr; Peterli 2018 SM-BOSS).
30-day mortality: approximately 0.1% at accredited U.S. MBSAQIP centers — comparable to gallbladder surgery.
Cost: roughly $15,000–$30,000 out of pocket in the U.S.; typically deductible + coinsurance when insurance covers.

What “bariatric surgery” actually means today

The label covers a group of stomach and intestinal procedures that produce durable weight loss by changing how much food fits comfortably in the stomach, how quickly it empties, and — in the malabsorptive procedures — how many calories and nutrients the small intestine actually absorbs. Modern bariatric surgery is almost entirely laparoscopic or robotic, most patients go home the day after surgery, and the hormonal effects on hunger, satiety, and glucose handling are as important as the anatomical restriction. It is not a cosmetic operation; the reason accredited centers refuse to operate outside the qualifying BMI and comorbidity criteria is that the risk-benefit case is built on treating obesity as a disease.

Four procedures cover more than 95% of bariatric operations performed in the U.S. today, and one endoscopic option (ESG) is expanding fast:

Sleeve gastrectomy — removes roughly 80% of the stomach along the greater curvature, leaving a banana-shaped tube. Restrictive with strong appetite-hormone effects (ghrelin drops sharply). The most common bariatric procedure worldwide.
Roux-en-Y gastric bypass — creates a small stomach pouch and reroutes it to the middle small intestine, bypassing the duodenum and proximal jejunum. Combined restrictive and moderately malabsorptive; strongest evidence for type 2 diabetes remission.
Duodenal switch / SADI-S (one-anastomosis) — pairs a sleeve gastrectomy with a longer intestinal bypass. Highest weight loss and highest T2D remission of the mainstream procedures, at the cost of the highest nutrient-deficiency burden.
Adjustable gastric banding — an inflatable silicone band around the upper stomach. Fully reversible, lowest weight loss, and now infrequently placed in the U.S. because of long-term failure and revision rates.

The fifth option worth naming is the endoscopic sleeve gastroplasty (ESG) — a non-surgical, incisionless suturing procedure done through the mouth. Weight loss lands between the band and the sleeve; reversibility and lower invasiveness are the appeal. For an all-in-one procedure walk-through with cost and eligibility, see bariatric surgery types compared.

Head-to-head: how the procedures compare

The table below summarizes the six evidence-based options against the four decision drivers that usually matter in a consult — one-year total weight loss, five-year durability, type 2 diabetes remission, and whether the anatomy is reversible.

Procedure	1-year TWL %	5-year TWL %	T2D remission	Reversibility	Reference
Sleeve gastrectomy	25–30%	15–20%	40–60%	Not reversible	Peterli 2018 SM-BOSS
Gastric bypass	30–35%	25%	50–70%	Reversible in principle	Peterli 2018 SM-BOSS; Courcoulas 2020 LABS
Adjustable gastric banding	15–20%	10%	20–30%	Fully reversible	O’Brien 2013 SOARD
Duodenal switch / SADI-S	35–40%	30%	70–80%	Not reversible	Salminen 2022 SLEEVEPASS 10-yr
ESG (endoscopic sleeve)	15–20%	12%	20–30%	Reversible	Sharaiha 2020 MERIT
Revision (band → sleeve/bypass)	15–25%	—	—	Procedure-dependent	Ma 2020 SOARD

Two practical patterns fall out of the table. First, weight loss and T2D remission scale together — the higher-intensity procedures produce larger losses and higher remission rates, but with the highest lifelong nutrition burden. Second, “reversibility” is more nuanced than it sounds: the band comes out cleanly, ESG sutures can be released, and bypass is reversible technically, but sleeve, duodenal switch, and SADI-S remove or reroute anatomy that does not go back.

Who qualifies

The 2022 ASMBS/IFSO joint guideline formally lowered the historic 1991 NIH thresholds. The current criteria for adults are:

BMI ≥ 35, with or without obesity-related comorbidities, or
BMI ≥ 30 with one obesity-related comorbidity — type 2 diabetes, hypertension, obstructive sleep apnea, non-alcoholic fatty liver disease, or established cardiovascular disease.

That lowered threshold (previously ≥ 40 alone, or ≥ 35 with a comorbidity) reflects a decade of trial data showing surgery is safer than long-term uncontrolled obesity in the 30–35 BMI band with metabolic disease. Insurers are gradually catching up; some still hold to the older thresholds, which is a common source of appeal-worthy denials.

For adolescents, the American Academy of Pediatrics 2023 guideline endorses referral for surgical evaluation at BMI ≥ 40, or ≥ 35 with a significant comorbidity, in patients who have reached Tanner stage 3 and near-final adult height. The Teen-LABS prospective cohort (Inge 2016, NEJM; 2019 5-year data) is the anchor evidence set — outcomes at 5 years matched adult results for weight loss and T2D remission, with a favorable safety profile in carefully selected patients. See adolescent and teen weight management for the multidisciplinary evaluation and family-based pathway.

Long-term outcomes

Three long-running trials and cohorts anchor how bariatric surgery is discussed in 2026:

STAMPEDE (Schauer 2017, NEJM, 5-year outcomes). Randomized adults with T2D and BMI 27–43 to intensive medical therapy alone versus medical therapy plus sleeve or bypass. Composite glycemic endpoint met by 5% in the medical arm versus 29% for bypass and 23% for sleeve. Surgical arms also had larger and more durable weight loss and lower medication burden at 5 years.
Swedish Obese Subjects (SOS) (Sjöström 2007 NEJM, 2020 20-yr extension). Prospective matched cohort of ~4,000 patients. Bariatric surgery reduced overall mortality by roughly 24% over 20 years and cut incident T2D, myocardial infarction, and total cancer mortality — the longest and largest bariatric outcome dataset in existence.
SPLENDID cancer cohort (Aminian 2022, JAMA). Matched retrospective analysis of ~30,000 patients showed a 32% relative reduction in obesity-associated cancer incidence and a 48% reduction in cancer mortality in the bariatric-surgery arm at 10 years, with the strongest signal for endometrial, colorectal, and hepatobiliary cancers.
Teen-LABS (Inge 2019 NEJM 5-year outcomes). Adolescents undergoing bypass had 26% total-weight loss and 86% T2D remission at 5 years — larger and more durable than any adult non-surgical option, with a safety profile comparable to gallbladder surgery.

What can go wrong and how often

Modern accredited-center bariatric surgery is safe in absolute terms, but no operation is risk-free. Understanding the actual event rates is the difference between an informed decision and either overconfidence or fear.

30-day mortality: roughly 0.1% at MBSAQIP-accredited U.S. centers — on par with gallbladder surgery and lower than hip replacement.
Serious 30-day complications (leak, bleed, VTE, deep infection): 3–5% overall; higher for revision cases and BMI > 50 patients. Anastomotic leak after bypass runs about 1–2%; sleeve staple-line leak about 1%.
Stricture: 3–5% after bypass, usually treatable endoscopically. Sleeve strictures are rarer but sometimes need revision to bypass.
Dumping syndrome: 25–50% after bypass, ~10–15% after sleeve. Usually manageable with meal composition; occasionally warrants dietary or medical intervention.
Long-term nutrient deficiencies: iron, B12, folate, calcium, vitamin D, thiamine, copper, and zinc all matter. Bypass and duodenal-switch patients need lifelong monitoring; sleeve patients need close follow-up in years 1–2 then annual labs. Full protocol details are in the bariatric post-op vitamin and nutrition protocol.
Bone-mineral density loss: measurable at 2 years post-sleeve and post-bypass (Yu 2017, Schafer 2017). Weight-bearing exercise, calcium citrate, and vitamin D repletion mitigate but do not eliminate the risk.
Hair shedding at 3–6 months: affects roughly 30–57% of patients; driven by the rapid calorie deficit and micronutrient dips. Nearly always self-limited if protein and vitamins are adequate.

Complication rates are strongly tied to surgeon volume, center accreditation, and appropriate pre-op optimization (smoking cessation, glycemic control, nutrition education). A structured 2-week pre-op liver-shrink protocol — typically a formula VLCD or a whole-food protein-sparing modified fast — is now standard at many programs; the ~10–12% reduction in liver volume simplifies laparoscopic access and lowers the intraoperative bleeding risk from a fatty left lobe. Choosing an MBSAQIP-accredited center is the single strongest lever a patient controls.

Cost, insurance, and access

Cash-pay bariatric surgery in the U.S. currently runs about $15,000–$30,000 for sleeve or bypass, depending on hospital, region, and included services. Insurance coverage is now the norm for commercial plans and Medicare when the patient meets BMI and comorbidity criteria and completes plan-specific requirements — typically prior authorization, 3–6 months of supervised weight-loss attempts, a psychological evaluation, nutrition classes, and treatment at an in-network center of excellence.

Ongoing lifetime costs after surgery matter too: bariatric multivitamins run $20–$50 per month, annual lab panels for nutrient monitoring, periodic follow-up visits, and — for a meaningful minority — the cost of managing dumping, reflux, or later revision. Financial-planning honesty at the consult stage prevents surprises at year two or three.

International medical tourism (Mexico, Turkey, Colombia) offers headline prices in the $4,000–$8,000 range for sleeve or bypass. The tradeoffs are real: variable center accreditation, no follow-up integration with U.S. care teams, higher re-admission and complication rates in the destination-back-home window, and no recourse for complications weeks later. A full walk-through of what patients actually pay — deductible and coinsurance realities, insurance-approval timelines, and the medical-tourism risk math — is in bariatric surgery cost and insurance coverage.

Bariatric surgery vs GLP-1 medications

The obvious 2026 question: should I try a GLP-1 first? The honest answer is that they are not interchangeable. GLP-1 medications (semaglutide, tirzepatide) deliver 15–22% mean total-weight loss in trials at full dose after 68–72 weeks; bariatric surgery delivers 25–35% at 12–18 months, with better durability at 5 and 10 years when patients maintain follow-up. Surgery wins on average magnitude and durability; GLP-1s win on reversibility, no operative risk, and the ability to stop and restart. For patients with a BMI in the 30–35 band, a metabolic comorbidity, and no urgency, a GLP-1 trial is often the reasonable first step. For BMI ≥ 40, poorly controlled T2D, or a decade of failed medical weight-loss attempts, surgery is often the better up-front choice. Increasingly the two are combined — pre-op GLP-1 for liver-size reduction, post-op GLP-1 for regain — and the choice is not either-or. Full side-by-side comparison at bariatric surgery vs GLP-1 medications.

What bariatric surgery does NOT do

The procedure is powerful, but it is not a substitute for the behavioral, nutritional, and psychological work that keeps the weight off. Being honest about the limitations up front is the strongest predictor of long-term success.

It does not eliminate the need for lifelong behavior change. Portion control, protein prioritization, hydration, structured eating, and regular activity are required inputs — not optional add-ons. The surgery makes those habits easier to sustain; it does not replace them.
It does not guarantee no regain. The STAMPEDE 5-year data showed 5–10 percentage points of regain from the 1-year peak on average, and a meaningful minority (20–30%) experience larger regain. Regain is treatable — but only when it is caught early and the bariatric team re-engaged.
It does not treat underlying eating disorders. Binge eating disorder is the most common eating-disorder finding in pre-bariatric clinics and predicts post-op binge re-emergence in 20–30% of patients when left untreated. Pre-op CBT-E is now standard at accredited centers. See binge eating disorder and weight loss for the pathway.
It is not a cosmetic operation. Weight loss of this magnitude often leaves excess skin; body-contouring is a separate later decision. Facial thinning and hair shedding are common transitional phenomena.
It is not a shortcut. The pre-op workup is 3–6 months; the recovery is 4–6 weeks; the post-op dietary and supplement discipline is lifelong.

Sources at a glance

Schauer PR et al. Bariatric surgery versus intensive medical therapy for diabetes (STAMPEDE) — 5-year outcomes. NEJM, 2017.
Sjöström L et al. Effects of bariatric surgery on mortality in Swedish obese subjects. NEJM, 2007; 20-year extension 2020.
Peterli R et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity (SM-BOSS). JAMA, 2018.
Salminen P et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss and quality of life at 7 years and 10-year extension (SLEEVEPASS). JAMA Surgery, 2018; 2022.
Courcoulas AP et al. Weight change and health outcomes at 3 years after bariatric surgery (LABS). JAMA, 2013; 7-year data 2020.
Sharaiha RZ et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT). Lancet, 2022.
Inge TH et al. Weight loss and health status 3 and 5 years after bariatric surgery in adolescents (Teen-LABS). NEJM, 2016; 2019.
Aminian A et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity (SPLENDID). JAMA, 2022.
O’Brien PE et al. Systematic review of medium-term weight loss after bariatric operations: laparoscopic adjustable gastric banding. SOARD, 2013.
Ma P et al. Revisional bariatric surgery: outcomes and complications. SOARD, 2020.

Sources

Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes (STAMPEDE). New England Journal of Medicine (2017).
Authors: Philip R. Schauer (MD), Deepak L. Bhatt (MD, MPH), John P. Kirwan (PhD), et al.
Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine (2007).
Authors: Lars Sjöström (MD, PhD), Krister Narbro (MD, PhD), Carl David Sjöström (MD), et al.
Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity (SM-BOSS). JAMA (2018).
Authors: Ralph Peterli (MD), Bettina Karin Wölnerhanssen (MD), Thomas Peters (MD), et al.
Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years (SLEEVEPASS). JAMA Surgery (2022).
Authors: Paulina Salminen (MD, PhD), Mika Helmiö (MD, PhD), Jari Ovaska (MD, PhD), et al.
Association of bariatric surgery with cancer risk and mortality (SPLENDID). JAMA (2022).
Authors: Ali Aminian (MD), Rickesha Wilson (MD), Alexander Zajichek (MS), et al.
Weight loss and health status 3 years after bariatric surgery in adolescents (Teen-LABS). New England Journal of Medicine (2016).
Authors: Thomas H. Inge (MD, PhD), Anita P. Courcoulas (MD, MPH), Todd M. Jenkins (PhD), et al.

Nora Kim

Medical weight loss writer

Nora Kim covers medical and surgical weight loss options, GLP-1 therapies, and evidence-based supplements. She focuses on explaining clinical research, safety considerations, and practical next steps so readers can discuss treatment choices with their care teams.